What is the address of LELIMA PHARMA?

The registered office of LELIMA PHARMA is located at Rue Croix Thomas 6, 1341 Ottignies-Louvain-la-Neuve.

Is LELIMA PHARMA still active?

Yes. According to the CBE (19 September 2026) LELIMA PHARMA is active, legal situation “Normale toestand”, started on 1 March 2018.

Is LELIMA PHARMA registered on Peppol?

Yes, LELIMA PHARMA is registered on the Peppol network with ID 0208:0691649590.

What is the enterprise number of LELIMA PHARMA?

The enterprise number of LELIMA PHARMA is BE0691649590.

When was LELIMA PHARMA founded?

LELIMA PHARMA was founded on 1 March 2018.

Who are the directors of LELIMA PHARMA?

According to the 2025 annual accounts, the directors of LELIMA PHARMA are: CEDIRC MEEUW.

Is LELIMA PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 1 March 2018; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did LELIMA PHARMA make in 2025?

LELIMA PHARMA posted a profit after taxes of € 45,404 in financial year 2025.

What is the revenue of LELIMA PHARMA?

As a small company, LELIMA PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 58,622.

LELIMA PHARMA (Private Limited) - Ottignies-Louvain-la-Neuve

Q: What does LELIMA PHARMA do?

LELIMA PHARMA is registered with the CBE as active in: Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies. Private Limited, started on 1 March 2018, 1 establishment.

Dossier LELIMA PHARMA, printed on 19 September 2026 from databakkes.be/en/0691649590/lelima-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

LELIMA PHARMA from Ottignies-Louvain-la-Neuve, company number BE0691649590, closed financial year 2025 with a result of € 45,404 after tax. For that financial year LELIMA PHARMA recorded a gross margin of € 58,622 and equity of € 193,380. Compared with financial year 2024, the result moved from € 45,392 to € 45,404. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 29, 2025.

What it is worth Growing

€ 193,380

▲ 31% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 45,404

Profit after tax over the fiscal year.

Cash in the bank

€ 98,277

▲ 6% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 174,780.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 4,060

▼ 42% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 1 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 2,638

▼ 61% vs 2024

€ 1,964 is repaid this year. At this pace the long-term loan is gone in ≈ 1 years.

Owed to suppliers

€ 2,650

▼ 30% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 8,171

▼ 34% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 52,704 Gross margin 2022: € 52,704 First fiscal year in the series	€ 64,050 Gross margin 2023: € 64,050 ▲ 22% vs 2022 (€ 52,704) Favourable step	€ 63,405 Gross margin 2024: € 63,405 ▼ 1% vs 2023 (€ 64,050) Unfavourable step	€ 58,622 Gross margin 2025: € 58,622 ▼ 8% vs 2024 (€ 63,405) Unfavourable step	▼ 8%
Profit after taxes	€ 39,978 Profit after taxes 2022: € 39,978 First fiscal year in the series	€ 44,006 Profit after taxes 2023: € 44,006 ▲ 10% vs 2022 (€ 39,978) Favourable step	€ 45,392 Profit after taxes 2024: € 45,392 ▲ 3% vs 2023 (€ 44,006) Favourable step	€ 45,404 Profit after taxes 2025: € 45,404 Unchanged (€ 45,392) Favourable step
Equity	€ 46,178 Equity 2022: € 46,178 First fiscal year in the series	€ 102,584 Equity 2023: € 102,584 ▲ 122% vs 2022 (€ 46,178) Favourable step	€ 147,976 Equity 2024: € 147,976 ▲ 44% vs 2023 (€ 102,584) Favourable step	€ 193,380 Equity 2025: € 193,380 ▲ 31% vs 2024 (€ 147,976) Favourable step	▲ 31%
Total debts	€ 37,576 Total debts 2022: € 37,576 First fiscal year in the series	€ 17,075 Total debts 2023: € 17,075 ▼ 55% vs 2022 (€ 37,576) Favourable step	€ 25,189 Total debts 2024: € 25,189 ▲ 48% vs 2023 (€ 17,075) Unfavourable step	€ 13,459 Total debts 2025: € 13,459 ▼ 47% vs 2024 (€ 25,189) Favourable step	▼ 47%
Cash	€ 63,694 Cash 2022: € 63,694 First fiscal year in the series	€ 73,405 Cash 2023: € 73,405 ▲ 15% vs 2022 (€ 63,694) Favourable step	€ 92,379 Cash 2024: € 92,379 ▲ 26% vs 2023 (€ 73,405) Favourable step	€ 98,277 Cash 2025: € 98,277 ▲ 6% vs 2024 (€ 92,379) Favourable step	▲ 6%
Retained profit	€ 39,978 Retained profit 2022: € 39,978 First fiscal year in the series	€ 83,984 Retained profit 2023: € 83,984 ▲ 110% vs 2022 (€ 39,978) Favourable step	€ 129,376 Retained profit 2024: € 129,376 ▲ 54% vs 2023 (€ 83,984) Favourable step	€ 174,780 Retained profit 2025: € 174,780 ▲ 35% vs 2024 (€ 129,376) Favourable step	▲ 35%
Dividend	€ 88,937 Dividend 2022: € 88,937 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 88,937) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 60 Bank debt 2023: € 60 Unchanged (€ 0) Unfavourable step	€ 6,814 Bank debt 2024: € 6,814 ▲ € 6,754 vs 2023 (€ 60) Unfavourable step	€ 2,638 Bank debt 2025: € 2,638 ▼ 61% vs 2024 (€ 6,814) Favourable step	▼ 61%
Balance sheet total	€ 83,754 Balance sheet total 2022: € 83,754 First fiscal year in the series	€ 119,659 Balance sheet total 2023: € 119,659 ▲ 43% vs 2022 (€ 83,754) Unchanged	€ 173,165 Balance sheet total 2024: € 173,165 ▲ 45% vs 2023 (€ 119,659) Unchanged	€ 206,839 Balance sheet total 2025: € 206,839 ▲ 19% vs 2024 (€ 173,165) Unchanged	▲ 19%

Key figures of LELIMA PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 October 2026.

What happened to LELIMA PHARMA?

What happened at LELIMA PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Sep 29, 2025 New annual accounts for financial year 2025: profit of € 45,404. Source: NBB ↗
2020 CEDIRC MEEUW became a director. NBB
Mar 1, 2018 New establishment in Ottignies-Louvain-la-Neuve. KBO
Mar 1, 2018 Start of the company according to the CBE. KBO

In short

From € 39,978 profit in 2022 to € 45,404 profit in 2025.

Paid € 48,660 in corporate taxes since 2022.

Best year ever: 2025, with € 45,404 profit.

Paid out € 88,937 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at LELIMA PHARMA? We notify you, reason included.

Follow LELIMA PHARMA

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

CEDIRC MEEUW

LELIMA PHARMA

Behind LELIMA PHARMA is CEDIRC MEEUW.

See the full network in the app

Directors

According to the 2025 annual accounts

CEDIRC MEEUW

Director

since 2020

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Croix Thomas 6

1341 Ottignies-Louvain-la-Neuve

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0691.649.590

VAT number

BE 0691.649.590

Registered office

Rue Croix Thomas 6, 1341 Ottignies-Louvain-la-Neuve

Names & denominations

LELIMA PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

1 March 2018

Peppol

Active · Active since 26 Nov 2025

Activities · NACE

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

View on CBE Public ↗ Annual accounts (NBB) ↗

LELIMA PHARMA

Financials

What happened to LELIMA PHARMA?

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions